General Medicine and Family Physicians and Dietitians who care for patients with binge eating disorder. Other health care providers, including nurse practitioners and physician assistants, may also participate.
Binge Eating Disorder, Eating Disorders, Obesity
Dr. Citrome is Clinical Professor of Psychiatry and Behavioral Sciences at New York Medical College in Valhalla, New York and has a private practice in Pomona, New York. He is the Editor-in-Chief of the International Journal of Clinical Practice, published by Wiley-Blackwell.
Dr. Citrome was the founding Director of the Clinical Research and Evaluation Facility at the Nathan S. Kline Institute for Psychiatric Research in Orangeburg, New York, and after nearly two decades of government service as a researcher in the psychopharmacological treatment of severe mental disorders, Dr. Citrome is now engaged as a consultant in clinical trial design and interpretation. Dr. Citrome is a member of the Board of Directors of the American Society of Clinical Psychopharmacology.
Main areas of interest include schizophrenia, bipolar disorder and major depressive disorder. He is a frequent lecturer on the quantitative assessment of clinical trial results using the evidence-based medicine metrics of number needed to treat and number needed to harm. Dr. Citrome is the author or co-author of over 400 research reports, reviews, chapters and abstracts in the scientific literature, is on the editorial board of 9 different medical journals, reviews for over 50 other journals, and has lectured extensively throughout the USA, Canada, Europe, and Asia.
1. | Assess the binge characteristics of BED in order to list how they are distinct from normal overeating and other eating disorders | 2. | Describe how the severity of BED is classified according to the DSM-5 diagnostic criteria |
3. | Evaluate how the addition of BED as a recognized disorder to the DSM-5 criteria can be used in practice to improve screening techniques and the diagnosis of BED in your at-risk patients | 4. | Identify misconceptions, biases, and negative attitudes commonly associated with BED in order to assess how they impact diagnosis, treatment, and communication with your at-risk patients |
1. | Assess the binge characteristics of BED in order to list how they are distinct from normal overeating and other eating disorders |
2. | Describe how the severity of BED is classified according to the DSM-5 diagnostic criteria |
3. | Evaluate how the addition of BED as a recognized disorder to the DSM-5 criteria can be used in practice to improve screening techniques and the diagnosis of BED in your at-risk patients |
4. | Identify misconceptions, biases, and negative attitudes commonly associated with BED in order to assess how they impact diagnosis, treatment, and communication with your at-risk patients |
Nature of Relationship | Commercial Entity |
Consultant/Advisory Board: marketing purposes and scientific information and clinical trial design | Actavis (Forest Laboratories), Alexza, Alkermes, Bristol-Myers Squibb, Eli Lilly, Forum (Envivo), Genentech, Janssen, Jazz Pharmaceuticals, Lundbeck, Merck, Medivation, Mylan, Novartis, Noven Pharmaceuticals, Otsuka, Pfizer, Reckitt Benckiser, Reviva, Shire Pharmaceuticals, Sunovion Pharmaceuticals, Takeda Pharmaceuticals, Teva Pharmaceutical Industries, Ltd. |
Shareholder (small number of shares) | Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer |
Promotional Speakers’ Bureau | Actavis (Forest Laboratories), AstraZeneca, Jazz Pharmaceuticals, Lundbeck, Novartis, Otsuka, Pfizer, Shire Pharmaceuticals, Sunovion Pharmaceuticals, Takeda Pharmaceuticals, Teva Pharmaceutical Industries, Ltd. |
Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. |